PYXS’ micvotabart pelidotin faces head & neck cancer competition, side effects and funding risk. See fall 2026 catalyst, ...

Maroussi, Greece – June 24, 2026 – Pyxis Tankers Inc. (Nasdaq Capital Market: PXS) (the "Company" or "Pyxis Tankers"), an international shipping company, today provided an operational update regarding ...

Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase ...

From cutting energy costs to unlocking new markets, see how companies in Singapore are proving that going green is a long-term driver for growth and resilience. Read more at straitstimes.com. Read ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pyxis Oncology (PYXS) and Glaukos (GKOS) with bullish sentiments. Unlock powerful investing tools and ...

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The ...

Muhsin discussed how BD is rolling out a new medication dispenser and a software platform that pulls together data from the company’s various devices.